I don't have a ready answer on your Humulin question, but I believe it is facing a patent expiration on the near horizon. It is an interesting point, though, and I'm sure we'll drill into it as time permits. Perhaps someone with some knowledge in this area can enlighten us.
As to your gratuitous comment on Biodel (And may I remind you that Biodel's go-it-alone Phase 3 trial ended in failure.: This is either fuzzy thinking or a subtle attempt to spread fear and uncertainty. You are implying that Biodel's fate is a predictor of Halozyme's because they attack the same target, ie.e, diabetes. I believe you are fully cognizant of the fact that the technologies are vastly different. So much for fuzzy thinking, then.
-Fritz
Market Data 
Markets 
AI
